GlaxoSmithKline (NYSE:GSK) enlarged prostate drug Jalyn faces the prospect of generic competition just over a year after launching in the U.S. market. In response to Watson’s application, GSK, which ...

The pharmaceutical industry mounted a new challenge to a federal plan that would require generic drug companies to take the initiative to update their labels to warn consumers whenever health risks ...

Pink eye drug AzaSite, a major component of Inspire Pharmaceutical‘s (NASDAQ:ISPH) portfolio and one of the key products sought by Merck (NYSE:MRK) in its $430 million acquisition of the North ...

AstraZeneca has been issued a generic challenge to its blockbuster cholesterol drug Crestor (rosuvastatin calcium) by Canada’s Cobalt pharmaceuticals. Cobalt is seeking approval to sell a copycat ...

The Generic Pharmaceutical Association took their fight directly to Big Pharma this week as the nation’s drug lobby hit the greens for an annual charity golf event held by Utah Sen. Orrin Hatch. As ...

Prescription drugs in the United States cost more than anywhere else in the world, and patients feel the pain of high prices every day. The cost is largely driven by the price of brand-name drugs, ...

Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the best mid-cap stocks with huge upside potential. H.C. Wainwright reaffirmed its Buy rating and $180 price target for Axsome Therapeutics Inc.

AstraZeneca’s Nexium could face generic competition much sooner than expected, and would-be investors should be wary, said brokerage firm Sanford C. Bernstein in an analyst note. The PPI, ...